Journal Mobile Options
Table of Contents
Vol. 185, No. 1-3, 2007
Issue release date: June 2007
Cells Tissues Organs 2007;185:100–103

Rho Proteins and Cell-Matrix Interactions in Cancer

Wu M. · Wu Z. · Merajver S.D.
Division of Hematology and Oncology and Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Dynamic interactions and dissolution of cell-extracellular matrix contacts are required steps to support cell growth and survival during cancer cell metastasis. Malignant cells acquire the ability to remodel extracellular matrix (ECM) and to modulate the expression of ECM receptors. Integrins are cellular receptors for molecules in the extracellular matrix. Integrin signaling is known to regulate metastatic cancer phenotypes by interacting synergistically with several signaling pathways, including the growth factor receptor pathway, the Ras-MAP kinase (Ras-MAPK) pathway and the Rho-effector pathway. In this mini-review, we discuss the functions of the Rho proteins and their relationship with other signaling pathways in matrix remodeling and integrin signaling of highly motile and invasive cancer cells.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Burbelo, P., A. Wellstein, R.G. Pestell (2004) Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 84: 43–48.
  2. Caswell, P.T., J.C. Norman (2006) Integrin trafficking and the control of cell migration. Traffic 7: 14.
  3. Clark, E.A., T.R. Golub, E.S. Lander, R.O. Hynes (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532–535.
  4. Collisson, E.A., C.G. Kleer, M. Wu, A. De, S.S. Gambhir, S.D. Merajver, M.S. Kolodney (2003) Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2: 941–948.
  5. Etienne-Manneville, S., A. Hall (2002) Rho GTPases in cell biology. Nature 420: 629–635.
  6. Giancotti, F.G., G. Tarone (2003) Positional control of cell fate through joint integrin-receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173.
  7. Guo, W., F.G. Giancotti (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816–826.
  8. Hakem, A., O. Sanchez-Sweatman, A. You-Ten, G. Duncan, A. Wakeham, R. Khokha, T.W. Mak (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19: 1974–1979.
  9. Hall, C.L., J. Dai, K.L. van Golen, E.T. Keller, M.W. Long (2006) Type I collagen receptor (alpha2beta1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66: 8648–8654.
  10. Hendrix, M.J.C., E.A. Seftor, A.R. Hess, R.E.B. Seftor (2005) The plasticity of melanoma cells and associated clinical implications; in Hearing VJ, Leong SPL (eds): From Melanocytes to Malignant Melanoma: the Progression to Malignancy. Totowa, Humana Press, pp 533–550.
  11. Ioachim, E., A. Charchanti, E. Briasoulis, V. Karavasilis, H. Tsanou, D.L. Arvanitis, N.J. Agnantis, N. Pavlidis (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38: 2362–2370.
  12. Jiang, K., J. Sun, J.Y. Cheng, S. Djeu, S. Wei, S. Sebti (2004) Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24: 5565–5576.
  13. Kaibuchi, K., S. Kuroda, M. Amano (1999) Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68: 459–486.
  14. Keely, P.J., E.V. Rusyn, A.D. Cox, L.V. Parise (1999) R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol 145: 1077.
  15. Kleer, C.G., K.L. van Golen, S.D. Merajver (2000) Molecular biology of breast cancer metastasis inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423–429.
  16. Madaule, P., T. Furuyashiki, T. Reid, T. Ishizaki, G. Watanabe, N. Morii, S. Narumiya (1995) Citron, a novel partner for the GTP-bound forms of rho and rac. FEBS Lett 377: 243–248.
  17. Mareel, M., A. Leroy (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83: 337–376.
  18. Maschler, S., G. Wirl, H. Spring, D.V. Bredow, I. Sordat, H. Beug, E. Reichmann (2005) Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 24: 2032–2041.
  19. Nissinen, L., J. Westermarck, L. Koivisto, V.M. Kahari, J. Heino (1998) Transcription of alpha2 integrin gene in osteosarcoma cells is enhanced by tumor promoters. Exp Cell Res 243: 1–10.
  20. Ren, X., W. Kiosses, M. Schwartz (1999) Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 18: 578–585.
  21. Sahai, E., C.J. Marshall (2002) ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 4: 408–415.
  22. Santala, P., H. Larjava, L. Nissinen, T. Riikonen, A. Maata, J. Heino (1994) Suppressed collagen gene expression and induction of alpha2beta1 integrin-type collagen receptor in tumorigenic derivatives of human osteogenic sarcoma (HOS) cell line. J Biol Chem 269: 1276–1283.
  23. Schmidt, A., A. Hall (2002) Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 16: 1587–1609.
  24. Sherman-Baust, C.A., A.T. Weeraratna, L.B. Rangel, E.S. Pizer, K.R. Cho, D.R. Schwartz, T. Shock, P.J. Morin (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3: 377–386.
  25. Stupack, D.G., D.A. Cheresh (2002) ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Science STKE 119: PE7.
  26. Suwa, H., G. Ohshio, T. Imamura, G. Watanabe, S. Arii, M. Imamura, S. Narumiya, H. Hiai, M. Fukumoto (1998) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77: 147–152.
  27. van Golen, K.L., S. Davies, Z.F. Wu, Y. Wang, C.D. Bucana, H. Root, S. Chandrasekharappa, M. Strawderman, S.P. Ethier, S.D. Merajver (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5: 2511–2519.
  28. van Golen, K., Z.F. Wu, X.T. Qiao, L.W. Bao, S.D. Merajver (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60: 5832–5838.
  29. Vial, E., E. Sahai, C.J. Marshall (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67–79.
  30. Wang, W., L.Y. Yang, G.W. Huang, W.Q. Lu, Z.L. Yang, J.Q. Yang, H.L. Liu (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90: 2349–2355.
  31. Webb, D.J., J.T. Parson, A.F. Horwitz (2002) Adhesion assembly, disassembly and turnover in migrating cells – over and over and over again. Nat Cell Biol 4: E97.
  32. Weber, K.S., C. Weber, G. Ostermann, H. Dierks, W. Nagel, W. Kolanus (2001) Cytohesin-1 is a dynamic regulator of distinct LFA-1 functions in leukocyte arrest and transmigration triggered by chemokines. Curr Biol 11: 1969.
  33. Wheeler, A.P., A.J. Ridley (2004) Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 301: 43–59.
  34. Wu, M., Z.F. Wu, C. Kumar-Sinha, A. Chinnaiyan, S.D. Merajver (2004) RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 84: 3–12.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00